Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis

Acta Haematologica

Volumn 111, Issue 4, 2004, Pages 221-224

  Thude, Hansjörg ^a,b   Gruhn, Bernd ^a   Werner, Uta ^a   Schorner, Uta ^a   Häfer, Ralf ^a   Zintl, Felix ^a   Barz, Dagmar ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

CD20; Flow cytometric analysis; ITP; Platelets; Rituximab

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CD20 ANTIBODY; CORTICOSTEROID; GLYCOPROTEIN IB; GLYCOPROTEIN IIIA; IMMUNOGLOBULIN; PREDNISONE; RHESUS D ANTIBODY; RITUXIMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL INFECTION; CASE REPORT; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS C; HLA SYSTEM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LYMPHOCYTOTOXICITY; LYMPHOPROLIFERATIVE DISEASE; MYELODYSPLASIA; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; TOXICITY TESTING; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CHRONIC DISEASE; DRUG MONITORING; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE COUNT; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; TREATMENT FAILURE;

EID: 2642549660     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077570     Document Type: Article

References (15)

1. George J, El-Havake M, Raskob G: Chronic idiopathic thrombopenic purpura. N Engl J Med 1997;331:207-211.
2. Karpatkin S: Autoimmune (idiopathic) thrombocytopenic purpura. Lancet 1997;349:1531-1536.
3. Stasi R, Pagano A, Stipa E, Amadori S: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952-957.
4. Reff M, Carner K, Chambers K, Chinn P, Leonard J, Raab R: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445.
5. Maloney D, Grillo-Lopez A, White C, Bodkin D, Schilder R, Neidhart J: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-2195.
6. McLaughlin P, Grillo-Lopez A, Link B, Levy R, Czuczman M, Williams M: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
7. Gopal A, Press O: Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999;134:445-450.
8. Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, De Vita S, Regazzi M, Baccarani M, Fanin R: B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002;87:189-195.
9. Giagounidis A, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, Aul C: Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002;69:95-100.
10. Delgado J, Bustos J, Jimenez-Yuste V, Hernandez-Navarro F: Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura. Haematologica 2002;87:215-216.
11. Saleh M, Gutheil J, Moore M, Bunch P, Butler J, Kunkel L, Grillo-Lopez A, Lobuglio A: A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27(suppl 12):99-103.
12. Ahrens N, Heymann G, Meyer O, Kiesewetter H, Salama A: Results of treatment with rituximab (anti-CD20) in three patients with autoimmune hemolytic anemia and/or immune thrombocytopenia and a concise review of reported cases. Infus Ther Transfus 2002;29:277-281.
13. Janisiw M, Eichelberger B, Koren D, Panzer S: Screening for platelet auto-antibodies by flow cytometry and their evalution by the MAIPA technique. Wien Klin Wochenschr 1998;110:531-534.
14. Bernstein N, Grillo-Lopez A, White C, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, Mc Laughlin P, Shen D: Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995-1001.
15. Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari A, Baccarani M, Fanin R: The B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003;88:538-546.